1. SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.
- Author
-
Haggenburg S, Hofsink Q, Rutten CE, Nijhof IS, Hazenberg MD, and Goorhuis A
- Subjects
- Adult, Humans, Immunity, Cellular, SARS-CoV-2, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, Hematologic Neoplasms complications
- Abstract
Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF